Review
Oncology
Morena Fasano, Ida D'Onofrio, Maria Paola Belfiore, Antonio Angrisani, Valentina Caliendo, Carminia Maria Della Corte, Mario Pirozzi, Sergio Facchini, Marianna Caterino, Cesare Guida, Valerio Nardone, Alfonso Reginelli, Salvatore Cappabianca
Summary: This review discusses the role of clinical management, geriatric evaluation, and therapeutic approaches in elderly patients with head and neck squamous cell carcinoma (HNSCC). Elderly HNSCC patients are often frail with multiple comorbidities and may receive suboptimal treatment. The review summarizes different strategies for the clinical management of elderly HNSCC patients.
Article
Nutrition & Dietetics
Yu-Ching Lin, Hang Huong Ling, Pei-Hung Chang, Yi-Ping Pan, Cheng-Hsu Wang, Wen-Chi Chou, Fang-Ping Chen, Kun-Yun Yeh
Summary: This study evaluated the difference in treatment-interval total body composition changes between oral cavity cancer patients with adjuvant CCRT and non-oral cavity cancer patients with primary CCRT. The study found that body composition parameters were progressively lost during CCRT in both subgroups, with different factors independently correlated with the interval changes of each body composition parameter for both groups.
Article
Oncology
Sachin R. Jhawar, Marcelo Bonomi, Paul M. Harari
Summary: The Oncology Grand Rounds series aims to help readers apply the results of key studies in clinical practice, using case presentations, literature reviews, and treatment recommendations to enhance understanding of the latest developments in oncology.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Dominic H. Moon, David J. Sher
Summary: Up to 40% of patients with metastatic head and neck squamous cell carcinoma have oligometastatic disease, which is associated with improved overall survival. Local ablative therapy and radiation therapy have shown promise in improving outcomes. Stereotactic ablative radiotherapy is a less invasive alternative to surgical resection, but more research is needed to determine its role.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Yazan Abu-Shama, Julia Salleron, Florent Carsuzaa, Xu-Shan Sun, Carole Pflumio, Idriss Troussier, Claire Petit, Matthieu Caubet, Arnaud Beddok, Valentin Calugaru, Stephanie Servagi-Vernat, Joel Castelli, Jessica Miroir, Marco Krengli, Paul Giraud, Edouard Romano, Jonathan Khalifa, Melanie Dore, Nicolas Blanchard, Alexandre Coutte, Charles Dupin, Shakeel Sumodhee, Yungan Tao, Vincent Roth, Lionel Geoffrois, Bruno Toussaint, Duc Trung Nguyen, Jean-Christophe Faivre, Juliette Thariat
Summary: A retrospective multicentric study on 322 patients with head and neck cancers of unknown primary (HNCUP) found that neck dissection (ND) improved progression-free survival (PFS) regardless of nodal stage, but did not improve survival rates. The extent of ND did not affect the benefits of the procedure, and the benefits decreased with a more advanced nodal stage.
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Oncology
Qiuji Wu, Chunmei Zhu, Shuyuan Zhang, Yunfeng Zhou, Yahua Zhong
Summary: Nimotuzumab-based concurrent chemoradiotherapy in head and neck cancers resulted in the least hematological toxicities, followed by cisplatin, nedaplatin, and lobaplatin. Patients require specific attention during concurrent chemoradiotherapy, especially in the presence of previous induction chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, General & Internal
Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert Haddad, Nabil F. Saba
Summary: Head and neck cancer is the seventh most common type of cancer worldwide, with the predominant risk factors being tobacco use, alcohol abuse, and oncogenic viruses. Treatment typically involves a multidisciplinary approach with surgery, radiotherapy, and systemic therapy, and is challenging due to site-specific and histology-specific variations.
Article
Oncology
Mang Zhang, Yu Chen, Weili Wu, Feng Jin, Yuanyuan Li, Jinhua Long, Xiuling Luo, Xiuyun Gong, Xiaoxiao Chen, Lina Liu, Hong Tang, Ziqi Wang
Summary: This study compared the toxicity and clinical efficacy of TL regimen and TPF regimen in the treatment of locally advanced head and neck squamous cell carcinoma. The results showed that TL regimen had advantages in reducing toxic side effects and offered better survival time for patients who underwent surgery and had N1 or N2 stage.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Christine H. Chung, Jiannong Li, Conor E. Steuer, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Maria I. Poole, Feifei Song, Juan C. Hernandez-Prera, Helen Molina, Bruce M. Wenig, Sunil Kumar, Charlotte Kuperwasser, Philip J. Stephens, Joaquim M. Farinhas, Dong M. Shin, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Nabil F. Saba, Marcelo Bonomi
Summary: A phase II multi-institutional clinical trial was conducted to evaluate the overall survival (OS) of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab and nivolumab. The results showed that this combination therapy was effective in both previously treated and untreated patients, and the expression of p16 and PD-L1 was associated with treatment response and survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn Marqueen, Kevin Sine, Dennis Mah, Brian Neal, Kaveh Zakeri, Jung J. Kang, Nadeem Riaz, Yao Yu, Sean M. McBride, Linda D. Chen, C. Jillian Tsai, Daphna Y. Gelblum, Robert H. Press, Loren S. Michel, Eric J. Sherman, David Pfister, Lara A. Dunn, Alan L. Ho, James Fetten, Richard J. Wong, Jay O. Boyle, Bhuvanesh Singh, Jennifer R. Cracchiolo, Ian Ganly, Marc A. Cohen, Nancy Y. Lee
Summary: This retrospective cohort study evaluated the outcomes and toxic effects of proton therapy reirradiation (PT-ReRT) in patients with head and neck squamous cell carcinoma. The study found that PT-ReRT can improve survival rates, but patients are still at risk of early and late complications.
Article
Cell Biology
Ziyue Gu, Yanli Yao, Guizhu Yang, Guopei Zhu, Zhen Tian, Rui Wang, Qi Wu, Yujue Wang, Yaping Wu, Lan Chen, Chong Wang, Jiamin Gao, Xindan Kang, Jie Zhang, Lizhen Wang, Shengzhong Duan, Zhongming Zhao, Zhiyuan Zhang, Shuyang Sun, Xindan Kang, Jie Zhang, Lizhen Wang, Shengzhong Duan, Zhongming Zhao, Zhiyuan Zhang, Shuyang Sun
Summary: This study establishes a large collection of HNSCC patient-derived cells and utilizes pharmacological screening and genomic analysis to provide precision treatment strategies for HNSCC patients. New biomarkers were discovered through this research.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Cristina Valero, Mahdi Golkaram, Joris L. Vos, Bin Xu, Conall Fitzgerald, Mark Lee, Shannon Kaplan, Catherine Y. Han, Xin Pei, Reith Sarkar, Lillian A. Boe, Abhinav Pandey, Elizabeth S. Koh, Charlotte L. Zuur, David B. Solit, Traci Pawlowski, Li Liu, Alan L. Ho, Diego Chowell, Nadeem Riaz, Timothy A. Chan, Luc G. T. Morris
Summary: This study analyzed the clinical and genomic features of 133 ICB-treated patients with R/M HNSCC and identified 6 molecular subtypes that determine the response to ICB therapy. A predictive model based on clinical and genomic features outperformed the current biomarker of TMB alone. This validated predictive tool can help with clinical risk stratification in patients with R/M HNSCC considering ICB treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Bhishamjit S. Chera, Siddharth H. Sheth, Shetal A. Patel, Dan Goldin, Kathe E. Douglas, Rebecca L. Green, Colette J. Shen, Gaorav P. Gupta, Dominic T. Moore, Juneko E. Grilley Olson, Jared M. Weiss
Summary: The study evaluated the safety and efficacy of adavosertib in patients with intermediate-risk/high-risk head and neck squamous cell carcinoma, and found that adavosertib at a dose of 100 mg twice daily with concurrent radiotherapy and cisplatin was both effective and tolerable for these patients.
Article
Oncology
Yanxiao Liu, Zhiyong Zheng, Minghao Li, Yaowen Zhang, Fujun Zhao, Heyi Gong, Haiqun Lin, Wei Huang, Xiangming Chen, Zhiqiao Xu, Xiaomin Li, Wenzhi Liu, Yanhui Cui, Anping Zheng, Baosheng Li
Summary: This phase II clinical trial compared the safety and efficacy of concurrent chemoradiotherapy using S-1 with radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma. The study found that concurrent chemoradiotherapy with S-1 had tolerable adverse effects and improved overall response rate and progression-free survival compared to radiotherapy alone.
INTERNATIONAL JOURNAL OF CANCER
(2022)